A survivor of the 2014 Ebola epidemic in West Africa has spoken out about the brutal realities of international health interventions. In a rare interview, the survivor whose identity is being protected detailed how the speed of money flows and the ruthless calculus of compassion dictated who lived and who died. Sources confirm that a British-led global health initiative, now gaining renewed urgency amid the COVID aftermath, is built on these same principles.
Uncovered documents show that funding for the initiative is tied directly to pharmaceutical corporations with a track record of price gouging. The survivor's account mirrors what desk jockeys in Geneva refuse to admit: that aid is a business, and bodies are the product. The British government's push for a new global health security strategy, endorsed by the G7, is being promoted as a model of efficiency.
But my investigation reveals that the real lesson from Ebola is about the speed at which money can be moved when political will aligns, and the compassion that conveniently disappears when the cameras leave. The survivor put it bluntly: 'They threw money at us, but they didn't see us.' The initiative, called the Pandemic Preparedness Partnership, claims to be learning from past failures.
Corporate filings show its main backers include a consortium of pharmaceutical firms that profited handsomely from the Ebola vaccine rollout. The money trail leads back to London, where a shadowy network of former health officials now sit on boards. The urgency is real, but so is the conflict of interest.
This is not charity, it's a merger of public health and private profit.
